崔冰

崔冰，博士，研究员，“协和”。2007年于中国医学科学院北京协和医学院药物研究所获药理学博士学位，同年进入美国加州大学圣迭戈分校（UCSD）肿瘤中心开始肿瘤生物学博士后研究。近年致力于肿瘤发生、转移、干性的分子机制及免疫治疗相关研究，迄今在包括Blood，PNAS，Cancer Res，Cancer Cell，JCI，Nat. Commun等期刊发表多篇论文，参与研发的人源化抗ROR1抗体已获批进入临床试验。累计发表47篇研究论文，其中国际核心期刊42篇。2015年10月依托天然药物活性物质与功能国家重点实验室组建肿瘤药理学实验室，现为中国医学科学院&北京协和医学院药物研究所研究员，博士生导师，于2016年获得协和称号。目前团队4名成员具有分子细胞生物学、免疫学、药理学和病理形态学等多学科基础研究经验。Email：cuibing@imm.ac.cn
主要研究领域：
目前课题组隶属于“天然药物活性物质与功能”国家重点实验室，主要研究领域包括肿瘤转移发生、肿瘤干性维持分子机制及药靶鉴定；肿瘤干细胞、非编码RNA在肿瘤生物学发挥的关键作用；肿瘤药理学、分子免疫药理学相关研究等。
教育与工作经历：
2015.-至今：研究员，中国医学科学院北京协和医学院药物研究所。
2012-2015：助理项目科学家，美国加州大学圣迭戈分校（UCSD）肿瘤中心。
2007-2012：博士后， 美国加州大学圣迭戈分校（UCSD）肿瘤中心，肿瘤生物学。
2004-2007：博士，北京协和医学院药物研究所，分子免疫药理学。
2001-2004：硕士，中国药科大学，心血管药理学。
1996-2001：学士，中国药科大学，药理学专业。
近期发表文章：
Complete Publication List:
https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/**/?sort=date&direction=descending
1. Sun W*, Yang ZN*, Lin H, Liu M, Zhao CX, Hou XY, Hu ZW, Cui B^#. Improvement in affinity and thermostability of a fully human antibody against interleukin-17A by yeast-display technology and CDR grafting. Acta Pharmaceutica Sinica B 2019; doi: 10.1016/j.apsb.2019.02.007
2. Cui B, Eyers PA, Dobens LL, Tan NS, Mace PD, Link WA, Kiss-Toth E , Keeshan K, Nakamura T, Pear WS, Feseha Y, Johnston J, Carracedo A, Scheideler M, llyas Z, Bauer RC, Erusalimsky JD, Grzesik D, Salamanca-Viloria J , Lv XX, Jin YS, Li K, Velasco G, Shang S, Lizcano JM, Zhang XW, Zhou JC, Yu JJ, Hua F, Wang F, Liu SS, Yu JM, Hu ZW#. Highlights of the 2nd International Symposium on Tribbles and Diseases: Tribbles tremble in therapeutics for immunity, metabolism, fundamental cell biology and cancer. Acta Pharmaceutica Sinica B 2019;9(2):443-454
3. Cui B*, Cao XT, Zou WP, Wan YH, Wang N, Wang YH, Li PP, Hua F, Liu YY, Zhang XW, Li K, Lv XX, Huang B^#, Hu ZW^#. Regulation of immune-related diseases by multiple factors: a meeting report of 2017 International Workshop of the Chinese Academy of Medical Sciences Initiative for Innovative Medicine on Tumor Immunology. Acta Pharmaceutica Sinica B 2017;7(4):532-540.
4. Cui B*, Ghia EM*, Chen L*, Rassenti LZ, , Zhang L, Neuberg DS, Wierda WG, Keating MJ, Rai KR, Kay NE, Brown JR, Byrd JC, Gribben JG, Greaves AW, Kipps TJ^#. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. (* co-first author) Blood 2016; 128(25):2931-2940.
5. Cui B*, Chen L*, Chen G, Lei B, Mraz M, Salcedo M, Rassenti L, Messer M, Calin GA, Croce CM, Kipps TJ. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. ( * co-first author) Blood 2014; 124(4):546-54.
6. Zhang S*, Cui B*, Lai H, Christina W, Liu G, Widhopf GF II , Wu RR, Lao F, Schwab R, Carson D, Kipps TJ. Depletion of ovarian cancer initiating cells by a monoclonal antibody against ROR1. ( * co-first author) Proc Natl Acad Sci U S A 2014;111(48):17266-71.
7. Widhopf II GF *, Cui B*, Ghia, EM, Chen LG, Messer K, Shen ZX, Briggs SP, Croce CM, Kipps TJ, ROR1 Can Interact With TCL1 And Enhance Leukemogenesis in Eµ-TCL1 Transgenic Mice. (* co-first author) Proc Natl Acad Sci U S A 2014;111(2):793-798.
8. Cui B*, Zhang SP*, Chen LG, Yu JQ, Widhopf II GF, Fecteau JF, Rassenti LZ, Kipps TJ, Targeting ROR1 Inhibits Epithelial-Mesenchymal Transition and Metastasis. (* co-first author) Cancer Research 2013;73(12):3649-60.
9. Li K, Zhang TT, Wang F, Cui B, Zhao CX, Yu JJ, Lv XX, Zhang XW, Yang ZN, Huang B, Li X, Hua F, Hu ZW. Metformin suppresses melanoma progression by inhibiting KAT5-mediated SMAD3 acetylation, transcriptional activity and TRIB3 expression. Oncogene. 2018. 37(22):2967-2981.
10. Liu YY, Liang XY, Dong WQ, Fang Y, Lv JD, Zhang TZ, Fiskesund R, Xie J, Liu JY, Yin XN, Jin X, Chen DG, Tang K, Ma JW, Zhang HF, Yu J, Yan J, Liang HP, Mo SQ, Cheng F, Zhou YB, Zhang HZ, Wang J, Li JN, Chen Y, Cui B, Hu ZW, Cao XT, Qin XF, Huang B. Tumor-Repopulating Cells Induce PD-1 Expression in CD8+ T Cells by Transferring Kynurenine and AhR Activation. Cancer Cell. 2018; 33(3):480-494.e7
11. Hasan MK, Yu J, Chen LG, Cui B, Shen ZX, Widhopf GF II, Rassenti LZ, Shen Z, Briggs SP, Kipps TJ^#. Wnt5a Induces ROR1 to Complex with HS1 to Enhance Migration of Chronic Lymphocytic Leukemia Cells. Leukemia, 2017;31(12):2615-2622.
12. Yu J, Chen L, Cui B, Wu CC, Choi MY , Chen Y, Zhang L, Rassenti L, Widhopf GF 2nd, Kipps TJ^#. Cirmtuzumab Inhibits Wnt5a-Induced Rac1 activation In Chronic Lymphocytic Leukemia Treated With Ibrutinib. Leukemia, 2017;31(6):1333-1339.
13. Li K, Wang F, Cao WB, Lv XX, Hua F, Cui B, Yu JJ, Zhang XW, Shang S, Liu SS, Yu JM, Han MZ, Huang B, Zhang TT, Li X, Jiang JD, Hu ZW^#. TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence. Cancer Cell. 2017;31(5):697-710.
14. Li PP*^,#, Liu SN*, Lu M*, Bandyopadhyay G, Oh D, Imamura T, Sears D, Shen ZF, Cui B, Kong LJ, Hou SC, Liang X, Iovino S, Watkins SM, Ying W, Osborn O, Wollam J, Brenner M, Olefsky JM^#. Hematopoietic-derived Galectin-3 Causes Cellular and Systemic Insulin Resistance. Cell. 2016;167(4):973-984.e12.
15. Yu J, Chen LG, Cui B, Widhopf GF II, Shen ZX, Wu RR, Zhang L, Zhang SP, Briggs SP, Kipps TJ. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest. 2016;126(2):585-98.
16. Hua F, Li K, Yu JJ, Lv XX, Yan J, Zhang XW, Sun W, Lin H, Shang S, Wang F, Cui B, Mu R, Huang B, Jiang JD, Hu ZW^#. TRB3 links insulin/IGF to tumor promotion by interacting with p62 and impeding autophagic/proteasomal degradations. Nat Commun. 2015;6:7951.
17. Fecteau JF, Corral LG, Ghia EM, Gaidarova S, Futalan D, Bharati IS, Cathers B, Schwaederlé M, Cui B, Lopez GA, Messmer D, and Kipps TJ^#. Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. Blood 2014;124(10):1637-44
18. Fecteau J, Messmer D, Zhang S, Cui B, Chen L, Kipps TJ^#. Impact of oxygen concentration on growth of mesenchymal stromal cells from the marrow of patients with chronic lymphocytic leukemia. Blood. 2013;121(6):971-4.
19. Zhang S, Wu CC, Fecteau JF, Cui B, Chen L, Zhang L, Wu R, Rassenti L, Lao F, Weigand S, Kipps TJ^#. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad Sci U S A. 2013;110(15):6127-32.
20. Zhang S, Chen L, Cui B, Chuang HY, Yu J, Wang-Rodriguez J, Tang L, Chen G, Basak GW, Kipps TJ^#. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One. 2012;7(3):e31127. IF:4.092

专利
1. Kipps TJ, Chen LG, Cui B. Cancer Treatment Combinations. US 62/355,171 Filed on 17 Jun, 2016
2. Kipps TJ, Yu J, Cui B, Chen LG, George WF, Prussak C, Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis. US 9,758,591B2, WOA1, filed on 15 Mar 2013, authorized on 12 Sep, 2017. (Develop anti-ROR1 antibody Cirmtuzumab. Phase I Clinical Trial is Initiated in September, 2014)
3. Kipps TJ, George WF, Cui B, Therapeutic antibodies against ROR-1 protein and methods for use of same. US 9,217,040 B2, WOA2, filed on 13 Jan 2012, authorized on 12 Dec, 2015. US 9,523,695 B2, filed on 4 Sep 2012, authorized on 20 Dec, 2016.
4. 胡卓伟，严君，何令帅，崔冰，杨红振，谢文杰，李平平. TLR4和TLR9激动剂复方在抑制肿瘤转移中的应用，发明专利专利号 CN B，授权日期2011年10月5日
5. 胡卓伟，杨红振， 崔冰 等. 抗Toll样受体2抗体抑制肿瘤转移的用途，发明专利专利号：CN B,申请日2006年9月21日，授权日2012年7月11日。
参编书籍
1. 胡卓伟，崔冰，杨红振，纤维化疾病的免疫学机制（第六章，171-201页），《器官纤维化基础及中医药防治》，牛建昭，贲长恩，人民卫生出版社，2008.01。
2. 胡卓伟，崔冰，王晓星，胰腺纤维化（第十章，399-428页），《器官纤维化基础及中医药防治》，牛建昭，贲长恩，人民卫生出版社，2008.01。
3. 闫慧敏，贲长恩，崔冰，器官纤维化实验中羟脯氨酸、胶原的检测方法（第二十三章，635-649页），《器官纤维化基础及中医药防治》，牛建昭，贲长恩，人民卫生出版社，2008.01。
4. 胡卓伟，崔冰，杨红振， 组织器官纤维化的研究方法与技术概述（第二十七篇第一章，1925-1939页）， 《现代药理实验方法》，张均田，杜冠华，中国协和医科大学出版社，2012.07。
5. 崔冰，闫慧敏，胡卓伟，肺纤维化实验方法和技术（第二十七篇第三章，1964-1969页），《现代药理实验方法》，张均田，杜冠华，中国协和医科大学出版社，2012.07。
6. 闫慧敏，崔冰，辛冰牧，胡卓伟，器官纤维化实验中羟脯氨酸、胶原的检测方法（第二十七篇第十二章，2058-2069页），《现代药理实验方法》，张均田，杜冠华，中国协和医科大学出版社，2012.07。

课题组主要成员
于金梅，博士，助理研究员
余娇娇，博士，助理研究员
赵其锦，博士，助理研究员
侯雪莹，学士，实习研究员